https://ujms.net/index.php/ujms/issue/feed Upsala Journal of Medical Sciences 2024-11-25T02:25:42-08:00 The UJMS Editorial Team michael.welsh@mcb.uu.se Open Journal Systems <p>Indexed in the Science Citation Index and MEDLINE, this open access journal welcomes both clinical and experimental contributions from across the entire medical field. It is read by an international audience,&nbsp;has no publishing charges and makes short decision times a high priority.</p> https://ujms.net/index.php/ujms/article/view/10770 Validity of prenatal AUDIT screening for alcohol disorders – a Nationwide Swedish register study 2024-11-25T02:25:42-08:00 Susanne Hesselman susanne.hesselman@uu.se Joline Asp joline.asp@uu.se Ulrika Pellas ulrika.pellas@regiondalarna.se Susanne Lager susanne.lager@uu.se Anna Wikman anna.wikman@uu.se <p><strong>Objective</strong>: This study aims to assess the external validity of the Alcohol Use Disorders Identification Test (AUDIT) in Swedish prenatal care as an indicator for alcohol-addiction disorders, and to characterize women with mismatched information in healthcare registers</p> <p><strong>Design</strong>: This study was designed as a National register-based study.</p> <p><strong>Setting</strong>: Sweden</p> <p><strong>Participants</strong>: The study sample included 739,735 pregnancies over the period 2014–2020.</p> <p><strong>Methods</strong>: Prospectively collected prenatal AUDIT screening in the&nbsp;<em>Swedish Pregnancy register</em>&nbsp;was linked to national health databases through individual identification number. The AUDIT score was dichotomized into &lt; 6 points (low-risk use) and ≥ 6 points (hazardous use). Alcohol addiction disorders were defined by a diagnostic code in&nbsp;<em>The Swedish National Patient Register</em>&nbsp;or drugs dispensed for alcohol dependence in the&nbsp;<em>Swedish Prescribed Drug Register</em>.</p> <p><strong>Primary Outcome Measures</strong>: The diagnostic properties of AUDIT were assessed based on sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), positive likelihood ratio (LR+), negative likelihood ratio (LR-), and accuracy (proportion of true positive and true negative) for an AUDIT score of ≥ 6 points for alcohol disorders. Women with mismatched information in the register were characterized and assessed by multinominal logistic regression, using women with matched information in the registers for reference.</p> <p><strong>Results</strong>: An alcohol-related disorder was recorded in 3.1%, while 25,770 (3.5%) had an AUDIT point ≥ 6. The diagnostic accuracy of the AUDIT ≥ 6 points for detection of an alcohol related disorder during a year prior to pregnancy was 95.7% (95% confidence interval [CI]: 95.7, 95.8), with a positive LR of 8.03 (95% CI: 7.5, 8.6). The sensitivity for detecting a pre-pregnancy alcohol related disorder was 33.0% (95% CI: 30.9, 35.1). Being young, nulliparous, of low education, and of Swedish origin increased the likelihood of being misclassified with the AUDIT. Prior psychiatric care was associated with false negatives, especially for women with neuropsychiatric disorders (odds ratio [OR]: 10.39, 95% CI: 9.89, 10.90).</p> <p><strong>Conclusions</strong>: The accuracy of AUDIT in screening for alcohol disorders at a population-based level was high, but only identified one third of women with alcohol-related disorders when using a cut-off of six points criterion.</p> 2024-11-25T02:19:58-08:00 Copyright (c) 2024 Susanne Hesselman, Joline Asp, Ulrika Pellas, Susanne Lager, Anna Wikman https://ujms.net/index.php/ujms/article/view/10664 Incidence of blindness in open-angle glaucoma in Sweden: a long-term follow-up study 2024-10-29T05:15:26-07:00 Curt Ekström curt.ekstrom@neuro.uu.se Christoffer Carlsson c2carlsson@gmail.com <p><strong>Background</strong>: Open-angle glaucoma (OAG) is a leading cause of irreversible blindness. There are no prospective studies on the risk of developing blindness in both eyes in individuals with definite OAG.</p> <p><strong>Methods</strong>: A total of 354 patients with newly diagnosed OAG, who had participated in four studies conducted at the Eye Department in Tierp, Sweden, from 1979 to 2006, were included in the investigation. Using the World Health Organization’s criteria for blindness, medical records, glaucoma case records, and visual fields were reviewed to identify patients who developed bilateral blindness. Incidence proportions and incidence rates were estimated. To assess potential risk factors for blindness, standardised morbidity ratios (SMRs) were calculated. The effects of age and sex were also analysed using Cox proportional hazard models.</p> <p><strong>Results</strong>: By the end of the study in August 2023, 33 cases of blindness caused by OAG had been found, corresponding to an incidence proportion of 9.3% (95% confidence interval [CI]: 6.5–12.8%). Within the first 20 years, 29 cases were detected, yielding a proportion of 8.2% (95% CI: 5.5–11.6%). The incidence rate was estimated to be 8.6 per 1,000 person-years (95% CI: 5.9–12.6 per 1,000 person-years). Glaucoma-related blindness was associated with male sex (SMR 2.33; 95% CI: 1.13–4.80). The hazard ratio was doubled for every 5 year of increasing age (2.21; 95% CI: 1.60–3.05).</p> <p><strong>Conclusion</strong>: In this study of blindness in newly diagnosed OAG in a Swedish population, approximately one in 10 patients progressed to bilateral blindness caused by the disease. Old age and male sex were identified as significant risk factors.</p> 2024-10-28T00:00:00-07:00 Copyright (c) 2024 Curt Ekström, Christoffer Carlsson https://ujms.net/index.php/ujms/article/view/10459 Tenecteplase compared to alteplase in real-world outcome: A Swedish Stroke Register study 2024-10-09T08:34:40-07:00 Mikael Skärlund mikael.skarlund@regionsormland.se Signild Åsberg signild.asberg@medsci.uu.se Marie Eriksson marie.eriksson@umu.se Erik Lundström erik.lundstrom@neuro.uu.se <p><strong>Background</strong>: Tenecteplase is increasingly used off-label as an alternative to alteplase for ischemic stroke thrombolysis. Our aim was to evaluate the safety of tenecteplase versus alteplase in comprehensive real-world data.</p> <p><strong>Methods</strong>: We compared the outcomes for adult patients with acute ischemic stroke treated with alteplase or tenecteplase, registered in the Swedish Stroke Register between January 1, 2018 and December 31, 2020. The primary outcome was symptomatic intracerebral hemorrhage or death during hospital stay. Secondary outcomes were death within 90 days, modified Rankin Scale at 90 days, and mean door-to-needle time (DNT).</p> <p><strong>Results</strong>: There were no significant differences in age or risk factors between 6,560 patients (45% women, mean age 74) treated with alteplase and 888 patients (43% women, mean age 74) treated with tenecteplase, although tenecteplase was more commonly used in non-university hospitals, hospitals with high use of thrombolysis, and in wake-up strokes. Tenecteplase was not non-inferior compared to alteplase in terms of symptomatic intracerebral hemorrhage or death during hospital stay (13.2% vs. 10.7%, absolute risk difference [95% confidence interval, CI] 2.5% [0.1 to 4.9%], adjusted odds ratio 1.44 [1.07–1.94]). There were no significant differences in functional outcome or death at 90 days, but tenecteplase was associated with decreased DNT (mean difference 9 min).</p> <p><strong>Conclusion</strong>: Tenecteplase was not non-inferior in safety outcome, although associated with decreased DNT. As accumulating randomized controlled studies support the non-inferiority of tenecteplase regarding functional outcome, it is important to keep scrutinizing the safety outcomes.</p> 2024-10-09T08:33:16-07:00 Copyright (c) 2024 The Authors https://ujms.net/index.php/ujms/article/view/10943 Self-reported sexually transmitted infections and associated risk factors among female university students 2024-10-01T08:54:21-07:00 Sofie Smeds sofie.smeds.1316@student.uu.se Cerisa Obern cerisa.obern@uu.se Inger Sundström Poromaa inger.sundstrom@uu.se Johan Westerbergh johan.westerbergh@ucr.uu.se Tanja Tydén tanja.tyden@uu.se Frida Gyllenberg frida.gyllenberg@uu.se <p><strong>Background</strong>: The spread of sexually transmitted infections (STIs) is an ongoing public health challenge, and awareness of risk factors is essential for designing effective preventive interventions. This study aimed to assess self-reported STI occurrences and identify risk factors and sexual behaviors associated with STIs among female university students.</p> <p><strong>Methods</strong>: This is a cross-sectional, online questionnaire study, including 384 female university students seeking contraceptive counseling at a gynecology clinic in Uppsala, Sweden, and reporting having had sex. Associated risk factors and behaviors were assessed by comparing those who reported STIs and those who did not.</p> <p><strong>Results</strong>: The mean age of participants was 22.8 years. Seventy-eight (20%) had contracted at least one STI, with seven (9%) experiencing multiple infections. Seventy-three (94%) reported first-date sexual activity without a condom among STI experienced. Chlamydia trachomatis was the most common STI pathogen (68% of all infections), followed by Herpes simplex virus (18%) and Mycoplasma genitalium (13%). Behavioral factors associated with self-reported STIs were first-date sexual activity without a condom, not using condom at first intercourse, younger age at first intercourse, a higher number of sexual partners overall and in the last 12 months, experience of anal sex, dating app usage, and regretting sexual activity after substance use (<em>P</em>&nbsp;&lt; 0.003 for all).</p> <p><strong>Conclusions</strong>: Condom use was low among the respondents, and STIs were common regardless of the high level of education in this group. Contraceptive counseling needs to highlight the importance of condom use in addition to contraceptive efficacy. It is also essential to consider the specific risk factors and behaviors prevalent among young adults to reduce the spread of STIs.</p> 2024-10-01T08:52:42-07:00 Copyright (c) 2024 The Authors https://ujms.net/index.php/ujms/article/view/10663 Survival in myotonic dystrophy type 1: a long time follow up-study with special reference to gastrointestinal symptoms 2024-09-17T15:30:19-07:00 Anders Rönnblom anders.ronnblom@akademiska.se Anders Ekbom anders.ekbom@ki.se <p><strong>Background</strong>: Myotonic dystrophy type 1 (DM1) is a monogenetic disease affecting many organs. Gastrointestinal symptoms are prevalent and of considerable consequences for affected individuals. The life expectancy is shortened and the objective of the study is to evaluate if gastrointestinal symptoms can predict the outcome of the disease.</p> <p><strong>Method</strong>: Fifty-one patients with DM1 were interviewed regarding symptoms from the gastrointestinal tract in the mid-1990s. Survival of all patients was evaluated in 2023 and the impact of symptoms on survival was assessed.</p> <p><strong>Results</strong>: At the beginning of the study, the mean age was 35.9 years, (median 37.0, 9–63). At the end of the study 47 out of the 51 patients were deceased at a mean age of 53.7 years (median 55.7, 32.5–79.0). Patients with the congenital form of DM1 (<em>n</em>&nbsp;= 6) died at an age of 46.0 years (median 45.2, 40.0–53.6). There was no correlation between the gastrointestinal symptoms and survival.</p> <p><strong>Conclusion</strong>: Albeit prevalent and of considerable clinical consequence, gastrointestinal symptoms are not correlated to survival in myotonic dystrophy type 1.</p> 2024-09-17T08:04:19-07:00 Copyright (c) 2024 Anders Rönnblom, Anders Ekbom https://ujms.net/index.php/ujms/article/view/10228 A case of enamel renal syndrome from a novel genetic mutation, multidisciplinary management and long-term prognosis 2024-09-13T13:22:04-07:00 Maria Erkapers maria.erkapers@regionuppsala.se Carina Frykholm carina.frykholm@akademiska.se Hans Furuland hans.furuland@medsci.uu.se Susanna Segerström susanna.segerstrom@regionuppsala.se Andreas Thor andreas.thor@akademiska.se <p><strong>Background</strong>: The heterogeneous features of enamel renal syndrome (ERS) make diagnosis and treatment challenging. The main symptoms are disturbed amelogenesis and nephrocalcinosis. Bi-allelic likely pathogenic (LP) or pathogenic (P) variants in&nbsp;<em>FAM20A</em>&nbsp;have been associated with the syndrome since 2012. Affected patients often receive extensive dental treatment because of deviant orofacial morphology. However, knowledge about long-term prognosis and treatment guidelines are still lacking. The complex nature of ERS might endanger both dental and general health. The purpose of this article is to highlight the risks of overlooking the symptoms of the syndrome, and to discuss management strategies, surveillance and prognosis.</p> <p><strong>Case presentation</strong>: We report the management of a case with suspected ERS after initial dental treatment elsewhere with no adjustment for the syndrome. Dental treatment was revised and followed for 8 years. Complementary medical examinations were conducted, and ERS was genetically confirmed, revealing homozygosity for a LP c.755_757del, p.(Phe252del) variant in&nbsp;<em>FAM20A</em>. The nephrological investigation revealed medullary calcium deposits, normal renal function and hypophosphatemia. Urine analysis revealed hypocitraturia and hypocalciuria. Accordingly, the patient now medicates with potassium citrate to decrease the risk of progressive renal stone formation.</p> <p><strong>Conclusion</strong>: We herein describe a patient with confirmed ERS with an 8-year follow-up. Diagnostic delay until adulthood led to complicated dental treatment. The results of nephrological investigations are presented. The importance of dental and medical multidisciplinary management in syndromic disorders affecting the formation of the enamel is also exemplified. The dental prognosis after rehabilitation is likely affected by anatomical variations and patient cooperation. The prognosis for renal function seems to be good. However, lifelong surveillance of renal function is recommended.</p> <p><strong>Registration</strong>: The ethics committee in Uppsala, Sweden, determined that ethical approval was not necessary in this case (2019-04835). Informed consent was obtained from the participant in writing and is documented in the medical records.</p> 2024-09-13T13:20:15-07:00 Copyright (c) 2024 Maria Erkapers, Carina Frykholm , Hans Furuland, Susanna Segerström, Andreas Thor https://ujms.net/index.php/ujms/article/view/10361 Trigger finger – Poor outcome of surgery associated with younger age, pain, psoriatic arthritis and atopic disease 2024-09-12T10:49:49-07:00 Björn Holm Bjorn.g.holm@uu.se Johan Rönnelid johan.ronnelid@igp.uu.se Eva Baecklund Eva.Baecklund@telia.com Monica Wiig monica.wiig@uu.se <p><strong>Background</strong>: Trigger finger, or stenosing tendovaginitis, is one of the most common causes of hand disability, where a finger or thumb painfully snaps and locks due to a tendon-sheath size mismatch at the A1 pulley. The exact aetiology of trigger finger is unknown, though it is associated with factors like diabetes, rheumatic disease and carpal tunnel syndrome. The main purpose of this prospective study was to explore clinical characteristics and comorbidities in a cohort of 139 patients who underwent surgery for trigger finger and find factors of importance for the outcome 1 year postoperatively.</p> <p><strong>Methods</strong>: Pain, range of motion, hand function evaluated by the Disabilities of the Arm Shoulder and Hand questionnaire as well as Quinnell grade of triggering were examined preoperatively. Symptom duration, working status, medical history and comorbidities at baseline were also noted. Further, range of motion was evaluated 3 months after surgery, pain and hand function were evaluated 3 and 12 months after surgery. An outcome scale with three levels was defined. The development of any new comorbidities was monitored during an extended postoperative observation period, with a mean duration of 70 months (range: 56–88 months).</p> <p><strong>Results</strong>: Poor outcome was strongly associated with younger age (<em>P</em>&nbsp;= 0.0009), a high level of preoperative pain in the operated hand (<em>P</em>&nbsp;= 0.0027), psoriatic arthritis (<em>P</em>&nbsp;= 0.021) and atopic disease (<em>P</em>&nbsp;= 0.028; odds ratio [OR]: 3.87, 95% confidence interval [CI]: 1.15–13.04). A low range of motion preoperatively did not affect the outcome. Carpal tunnel syndrome was the most common comorbidity but did not affect the outcome. A good preoperative range of motion, good hand function and less pain were associated with better outcomes.</p> <p><strong>Conclusion</strong>: Younger age, a high level of preoperative pain, psoriatic arthritis and atopic disease were factors associated with a worse outcome of trigger finger surgery. Pain and disability decreased 3 months postoperatively and continued to decrease between 3 and 12 months.</p> 2024-09-12T10:47:40-07:00 Copyright (c) 2024 The Authors https://ujms.net/index.php/ujms/article/view/10698 Relationship status among lesbian and heterosexual couples 8–10 years after undergoing assisted reproductive treatment in Sweden 2024-09-05T12:35:14-07:00 Konstantinos Chasapis konstantinos.chasapis@uu.se Gunilla Sydsjö Gunilla.Sydsjo@regionostergotland.se Agneta Skoog Svanberg Agneta.Skoog_Svanberg@kbh.uu.se Claudia Lampic claudia.lampic@ki.se Evangelia Elenis evangelia.elenis@kbh.uu.se <p><strong>Background</strong>: Infertility along with fertility treatments has been reported to have a devastating effect on the well-being of the individuals involved as well as their relationship. So far, the studies exploring the impact on the relationship have mainly focused on heterosexual couples facing infertility and undergoing treatment. There is, therefore, a lack of data on the potential role of sexual orientation, gamete origin, as well as treatment success on the risk of separation after fertility treatment. The purpose of this study was, thus, to explore whether sexual orientation, donation treatment, and fertility success affected the relationship well-being and to explore various separation-related aspects.</p> <p><strong>Methods</strong>: We have performed a prospective cohort study of heterosexual and homosexual couples undergoing fertility treatment with autologous and donated gametes in Sweden and followed them for up to 10 years after receiving fertility treatment. In the current follow-up study, 660 individuals have been included.</p> <p><strong>Results</strong>: Almost 39% of lesbian couples participating reported having separated as opposed to 11–17% of heterosexual couples undergoing treatment with own or donated gametes. Neither background factors nor treatment success protected against separation. By using the relationship satisfaction&nbsp;<em>ENRICH</em>&nbsp;tool, we were able to demonstrate that dissatisfaction of one of the lesbian spouses or heterosexual spouses undergoing oocyte donation increased significantly the risk of separation 8–10 years after treatment commencement.</p> <p><strong>Conclusion</strong>: The findings can be used by fertility clinics to provide relationship tools to the treated couples in order to help them nurture their relationship and decrease the risk of separation in the long run.</p> 2024-09-05T12:34:10-07:00 Copyright (c) 2024 The Authors https://ujms.net/index.php/ujms/article/view/10603 Personality vulnerability to depression, resilience, and depressive symptoms: epigenetic markers among perinatal women 2024-09-10T03:53:27-07:00 Rita T. Amiel Castro r.castro@psychologie.uzh.ch Elena Gardini emma.csemiczky@openacademia.net Stavros I. Iliadis emma.csemiczky@openacademia.net Ulrike Ehlert emma.csemiczky@openacademia.net Theodora Kunovac Kallak emma.csemiczky@openacademia.net Alkistis Skalkidou emma.csemiczky@openacademia.net <p><strong>Background</strong>: We examined differences in DNA methylation patterns in the&nbsp;<em>NR3C1</em>&nbsp;and&nbsp;<em>FKBP5</em>&nbsp;genes in relation to personality vulnerability to depression, resilience, and perinatal depressive symptoms, whilst also considering possible moderating effects of childhood traumatic events.</p> <p><strong>Methods</strong>:&nbsp;<em>N</em>&nbsp;= 160 perinatal women were assessed at late pregnancy and 1 year postpartum for personality vulnerability to depression, resilience, depressive symptoms, and childhood traumatic events with self-reported questionnaires.&nbsp;<em>NR3C1</em>&nbsp;and&nbsp;<em>FKBP5</em>&nbsp;methylation markers were analyzed via sodium bisulfite sequencing. Associations of methylation markers with the above mentioned variables were tested using multivariable regressions.</p> <p><strong>Results</strong>:&nbsp;<em>NR3C1</em>&nbsp;methylation at CpGs 1, 4 and average methylation sites were negatively associated with resilience;&nbsp;<em>NR3C1</em>&nbsp;methylation at CpG 2 was positively associated with postpartum depressive symptoms; methylation at CpG 4 was positively associated with prenatal depressive symptoms. The interaction between current distress due to interpersonal traumatic events and&nbsp;<em>NR3C1</em>&nbsp;CpG sites in relation to personality vulnerability was significant on CpG sites 3 and 4, whereas the interaction between current distress due to total traumatic events and&nbsp;<em>NR3C1</em>&nbsp;in relation to personality vulnerability was significant on CpG site 2.&nbsp;<em>FKBP5</em>&nbsp;showed no significant associations with the outcomes.</p> <p><strong>Conclusions</strong>: This study identified associations between NR3C1 methylation and resilience as well as perinatal depressive symptoms. Interestingly, an interaction between early trauma and personality vulnerability was noted. Our findings on these specific DNA methylation markers may, if replicated and integrated into risk prediction models, contribute to early diagnosis of mothers at risk, targeted health promotion, and early interventions.</p> 2024-09-04T05:24:49-07:00 Copyright (c) 2024 Rita T. Amiel Castro, Elena Gardini, Stavros I. Iliadis, Ulrike Ehlert, Theodora Kunovac Kallak, Alkistis Skalkidou https://ujms.net/index.php/ujms/article/view/10740 Lung function at 1-year follow-up in patients with persistent dyspnea after mild COVID-19 – comparisons with moderate and critical COVID-19 2024-09-04T05:10:43-07:00 Marta A. Kisiel marta.kisiel@medsci.uu.se Carl-Johan Neiderud emma.csemiczky@openacademia.net Emil Ekbom emma.csemiczky@openacademia.net Gabriel Westman emma.csemiczky@openacademia.net Helena Janols emma.csemiczky@openacademia.net Miklos Lipcsey emma.csemiczky@openacademia.net Robert Frithiof emma.csemiczky@openacademia.net Michael Hultström emma.csemiczky@openacademia.net Andrei Malinovschi emma.csemiczky@openacademia.net <p><strong>Aim</strong>: To assess lung function in patients with persistent dyspnea 1 year after mild coronavirus disease 2019 (COVID-19) and compare with those hospitalized with moderate or critical COVID-19.</p> <p><strong>Methods</strong>: Adults with confirmed severe acute respiratory syndrome coronavirus-2 infection with mild COVID-19 and persistent dyspnea (<em>n</em>&nbsp;= 18) or with moderate (<em>n</em>&nbsp;= 34) or critical COVID-19 (<em>n</em>&nbsp;= 19) were followed up 11–13 months after initial infection. Inclusion criteria were age &lt; 65 years, no smoking history, and no preexisting respiratory diseases. Sociodemographic and clinical data were collected, and patients underwent spirometry and measurement of diffusing capacity for carbon monoxide (D<sub>LCO</sub>).</p> <p><strong>Results</strong>: The non-hospitalized patients were significantly younger and more often female compared with those in the moderate and critical groups (<em>P</em>&nbsp;= 0.002 and&nbsp;<em>P</em>&nbsp;&lt; 0.001, respectively). No significant differences in comorbidities or body mass index (BMI) were noted between severity groups. An obstructive spirometry pattern (ratio of forced expiratory volume during the first exhalation second to forced vital capacity under the lower limit of normal (LLN)) was found in 5.6, 5.9, and 5.3% of patients in the mild, moderate, and critical groups, respectively (<em>P</em>&nbsp;= 0.995). Abnormal D<sub>LCO</sub>&nbsp;(&lt; LLN) rates were seen in 5.6, 16.7, and 47.4% in the mild, moderate, and critical groups, respectively (<em>P</em>&nbsp;= 0.018). D<sub>LCO</sub>, expressed as a&nbsp;<em>z</em>-score, was significantly lower in the critical group compared with the mild group after adjustment for age, sex, and BMI.</p> <p><strong>Conclusion</strong>: Only a few subjects with mild COVID-19 and persistent dyspnea had abnormal lung function 1 year after initial infection, assessed based on spirometry and D<sub>LCO</sub>&nbsp;measurements. An obstructive spirometry pattern at 1-year follow-up was uncommon even in patients with moderate or critical COVID-19. Impaired D<sub>LCO</sub>&nbsp;was more common in patients with critical COVID-19.</p> 2024-09-03T07:25:34-07:00 Copyright (c) 2024 Marta Kisiel, Carl-Johan Neiderud, Emil Ekbom, Gabriel Westman, Helena Janols, Miklos Lipcsey, Robert Frithiof, Michael Hultström, Andrei Malinovschi https://ujms.net/index.php/ujms/article/view/10799 Anatomical and subcortical invasiveness in diffuse low-grade astrocytomas differ between IDH status and provide prognostic information 2024-09-10T05:11:13-07:00 Maria Zetterling maria.zetterling@neuro.uu.se Markus Fahlström markus.fahlstrom@uu.se Francesco Latini francesco.latini@neuro.uu.se <p><strong>Background</strong>: Diffuse astrocytomas preferentially infiltrate eloquent areas affecting the outcome. A preoperative understanding of isocitrate dehydrogenase (IDH) status may offer opportunities for specific targeted therapies impacting treatment management. The aim of this study was to analyze clinical, topographical, radiological in WHO 2 astrocytomas with different IDH status and the long-term patient’s outcome.</p> <p><strong>Methods</strong>: A series of confirmed WHO 2 astrocytoma patients (between 2005 and 2015) were retrospectively analyzed. MRI sequences (FLAIR) were used for tumor volume segmentation and to create a frequency map of their locations into the Montreal Neurological Institute (MNI) space. The Brain-Grid (BG) system (standardized radiological tool of intersected lines according to anatomical landmarks) was used as an overlay for infiltration analysis of each tumor. Long-term follow-up was used to perform a survival analysis.</p> <p><strong>Results</strong>: Forty patients with confirmed IDH status (26 IDH-mutant, IDHm/14 IDH-wild type, IDHwt) according to WHO 2021 classification were included with a mean follow-up of 7.8 years. IDHm astrocytomas displayed a lower number of BG-voxels (<em>P</em>&nbsp;&lt; 0.05) and were preferentially located in the anterior insular region. IDHwt group displayed a posterior insular and peritrigonal location. IDHwt group displayed a shorter OS compared with IDHm (<em>P</em>&nbsp;&lt; 0.05), with the infiltration of 7 or more BG-voxels as an independent factor predicting a shorter OS.</p> <p><strong>Conclusions</strong>: IDHm and IDHwt astrocytomas differed in preferential location, number of BG-voxels and OS at long follow-up time. The number of BG-voxels affected the OS in IDHwt was possibly reflecting higher tumor invasiveness. We encourage the systematic use of alternative observational tools, such as gradient maps and the Brain-Grid analysis, to better detect differences of tumor invasiveness in diffuse low-grade gliomas subtypes.</p> 2024-09-03T07:04:29-07:00 Copyright (c) 2024 Maria Zetterling, Markus Fahlström, Francesco Latini https://ujms.net/index.php/ujms/article/view/10376 The risk of hemochromatosis among first- and second-generation immigrants: a cohort study of the total population in Sweden 2024-09-10T04:00:44-07:00 Per Wändell per.wandell@ki.se Xinjun Li xinjun.li@med.lu.se Axel C. Carlsson axel.carlsson@ki.se Jan Sundquist jan.sundquist@med.lu.se Kristina Sundquist kristina.sundquist@med.lu.se <p><strong>Purpose</strong>: We aimed to analyze the risk of hereditary hemochromatosis (HH) among first-generation and second-generation immigrants in Sweden using Swedish-born individuals and Swedish-born individuals with Swedish-born parents as referents, respectively.</p> <p><strong>Methods</strong>: All individuals aged 18 years of age and older,&nbsp;<em>n</em>&nbsp;= 6,180,500 in the first-generation study, and&nbsp;<em>n</em>&nbsp;= 4,589,930 in the second-generation study were included in the analyses. HH was defined as at least one registered diagnosis International Classification of Diseases 10th edition (E83.1) in the National Patient Register between January 1, 1998 and December 31, 2018. Cox regression was used to estimate the hazard ratios (HRs) with 99% confidence intervals (CI) owing to multiple testing, of incident HH with adjustments for age, cancer, other comorbidities, and socio-demographics.</p> <p><strong>Results</strong>: In the first-generation study, there were 5,112 cases of HH, and in the second-generation study 4,626 cases of HH. The adjusted HRs for first-generation men and women overall were 0.72 (99% CI: 0.63–0.82) and 0.61 (99% CI: 0.52–0.72), respectively, and for the second-generation men and women 0.72 (99% CI: 0.62–0.83) and 0.97 (99% CI: 0.83–1.14), respectively, with a higher risk found only among first-generation men from Western Europe, HR 1.47 (99% CI: 1.05–2.06), compared to the control group.</p> <p><strong>Conclusions</strong>: Our findings indicate that the overall risk of HH was lower among both first-generation and second-generation immigrants when compared to individuals born in Sweden or with Swedish-born parents. An elevated risk for HH was observed exclusively among first-generation men originating from Western Europe. These findings represent new knowledge and should be of global interest.</p> 2024-08-09T07:38:35-07:00 Copyright (c) 2024 Per Wändell, Xinjun Li, Axel C. Carlsson, Jan Sundquist, Kristina Sundquist https://ujms.net/index.php/ujms/article/view/10791 Nuclear factor erythroid 2-related factor 2 activation in streptozotocin-induced diabetic rats normalize renal hemodynamics and oxygen consumption 2024-07-09T04:00:00-07:00 Patrik Persson patrik.persson@mcb.uu.se <p><strong>Background</strong>: Diabetic kidney disease is a major contributor to end stage renal disease. A change in kidney oxygen homeostasis leading to decreased tissue oxygen tension is an important factor initiating alterations in kidney function in diabetes. However, the mechanism contributing to changed oxygen homeostasis is still unclear. Hyperglycemia-induced production of reactive oxygen species and an altered response to them have previously been demonstrated. In the present study, chronic treatment with DL-sulforaphane to induce nuclear factor erythroid 2-related factor 2 (Nrf2) expression, a master transcriptional regulator binding to antioxidant response elements inducing increased protection against reactive oxygen species, is studied.</p> <p><strong>Methods</strong>: Sprague–Dawley rats were made diabetic using streptozotocin and either left untreated or received daily subcutaneous injections of DL-sulforaphane for 4 weeks. Age-matched non-diabetic rats served as controls. After 4 weeks of treatment, rats were anesthetized using thiobutabarbital, and kidney functions were studied in terms of glomerular filtration rate (GFR), renal blood flow (RBF), sodium transport, kidney oxygen consumption, and kidney oxygen tension. Mitochondria was isolated from kidney cortical tissue and investigated using high-resolution respirometry.</p> <p><strong>Results</strong>: GFR was increased in diabetics but not RBF resulting in increased filtration fraction in diabetics. DL-sulforaphane treatment did not affect RBF and GFR in controls but decreased the same parameters in diabetics. Increased GFR resulted in increased sodium transport and oxygen consumption, hence decreased efficiency in diabetics compared to controls. Increased oxygen consumption in diabetics resulted in decreased cortical tissue oxygen tension. DL-sulforaphane treatment decreased oxygen consumption in diabetics, whereas transport efficiency was not significantly affected. DL-sulforaphane treatment increased cortical pO<sub>2</sub>&nbsp;in diabetics.</p> <p><strong>Conclusions</strong>: DL-sulforaphane treatment affects renal hemodynamics, improving cortical oxygen tension but not mitochondrial efficiency.</p> 2024-07-09T03:58:54-07:00 Copyright (c) 2024 Patrik Persson https://ujms.net/index.php/ujms/article/view/10465 Central obesity and fat-free mass are associated with a larger spleen volume in the general population 2024-05-30T02:59:59-07:00 Mohammed Farah Mahmoud Mousa emma.csemiczky@openacademia.net Naeem Muhammad muhammad.naeem@stud.uni-greifswald.de Saima Bibi emma.csemiczky@openacademia.net Robin Bülow emma.csemiczky@openacademia.net Martin Bahls emma.csemiczky@openacademia.net Ulrike Siewert-Markus emma.csemiczky@openacademia.net Philipp Töpfer emma.csemiczky@openacademia.net Ali Aghdassi emma.csemiczky@openacademia.net Muhammad Nasir Khan Khattak emma.csemiczky@openacademia.net Henry Völzke emma.csemiczky@openacademia.net Marcello RP Markus emma.csemiczky@openacademia.net Till Ittermann emma.csemiczky@openacademia.net <p><strong>Background and aim</strong>: As the spleen plays a significant role in immunity, the aim was to investigate the associations of different body composition markers derived from various sources with spleen volume in a general population sample.</p> <p><strong>Materials and methods</strong>: Cross-sectional data of 1095 individuals (570 women; 52%) aged between 30 and 90 years were collected in the Study of Health in Pomerania (SHIP-START-2). We measured spleen volume by magnetic resonance imaging (MRI).</p> <p>Body composition markers were derived from classic anthropometry, bioelectrical impedance analysis, including absolute fat mass (FM) and fat-free mass (FFM), as well as from MRI, including visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT), and liver fat content. Sex-stratified-adjusted linear regression models were used to analyze the associations of body composition markers with spleen volumes.</p> <p><strong>Results</strong>: We observed positive associations of body mass index, body weight, waist circumference, hip circumference, waist-to-height ratio, absolute FM, absolute FFM, and VAT and SAT with spleen volume in men and women. An 8.12 kg higher absolute FFM was associated with a 38.4 mL (95% confidence interval [CI]: 26.7–50.1) higher spleen volume in men and a 5.21 kg higher absolute FFM with a 42.6 mL (95% CI: 26.2–59.0) higher spleen volume in women.</p> <p><strong>Conclusion</strong>: Our findings indicate that obesity-related body composition markers and FFM are associated with a higher spleen volume. Particularly, higher absolute FFM showed a strong association with a larger spleen volume in both men and women. Further studies are warranted to understand the clinical significance of body composition markers on large spleen volume.</p> 2024-05-30T02:52:47-07:00 Copyright (c) 2024 Mohammed Farah Mahmoud Mousa, Naeem Muhammad, Saima Bibi, Robin Bülow, Martin Bahls, Ulrike Siewert-Markus, Philipp Töpfer, Ali Aghdassi, Muhammad Nasir Khan Khattak, Henry Völzke, Marcello RP Markus, Till Ittermann https://ujms.net/index.php/ujms/article/view/10585 Indium-111 radiolabelling of a brain-penetrant Aβ antibody for SPECT imaging 2024-05-20T14:55:20-07:00 Tobias Gustavsson tobias.gustavsson@sund.ku.dk Matthias M. Herth matthias.herth@sund.ku.dk Dag Sehlin dag.sehlin@pubcare.uu.se Stina Syvänen stina.syvanen@pubcare.uu.se <p><strong>Background</strong>: The development of bispecific antibodies that can traverse the blood–brain barrier has paved the way for brain-directed immunotherapy and when radiolabelled, immunoPET imaging. The objective of this study was to investigate how indium-111 (<sup>111</sup>In) radiolabelling with compatible chelators affects the brain delivery and peripheral biodistribution of the bispecific antibody RmAb158-scFv8D3, which binds to amyloid-beta (Aβ) and the transferrin receptor (TfR), in Aβ pathology-expressing tg-ArcSwe mice and aged-matched wild-type control mice.</p> <p><strong>Methods</strong>: Bispecific RmAb158-scFv8D3 (biAb) was radiolabelled with&nbsp;<sup>111</sup>In using CHX-A”-DTPA, DOTA, or DOTA-tetrazine (DOTA-Tz). Affinity toward TfR and Aβ, as well as stability, was investigated&nbsp;<em>in vitro</em>. Mice were then intravenously administered with the three different radiolabelled biAb variants, and blood samples were collected for monitoring pharmacokinetics. Brain concentration was quantified after 2 and 72 h, and organ-specific retention was measured at 72 h by gamma counting. A subset of mice also underwent whole-body Single-photon emission computed tomography (SPECT) scanning at 72 h after injection. Following post-mortem isolation, the brains of tg-ArcSwe and WT mice were sectioned, and the spatial distribution of biAb was further investigated with autoradiography.</p> <p><strong>Results</strong>: All three [<sup>111</sup>In]biAb variants displayed similar blood pharmacokinetics and brain uptake at 2 h after administration. Radiolabelling did not compromise affinity, and all variants showed good stability, especially the DOTA-Tz variant. Whole-body SPECT scanning indicated high liver, spleen, and bone accumulation of all [<sup>111</sup>In]biAb variants. Subsequent&nbsp;<em>ex vivo</em>&nbsp;measurement of organ retention confirmed SPECT data, with retention in the spleen, liver, and bone – with very high bone marrow retention.&nbsp;<em>Ex vivo</em>&nbsp;gamma measurement of brain tissue, isolated at 72 h post-injection, and&nbsp;<em>ex vivo</em>&nbsp;autoradiography showed that WT mice, despite the absence of Aβ, exhibited comparable brain concentrations of [<sup>111</sup>In]biAb as those found in the tg-ArcSwe brain.</p> <p><strong>Conclusions</strong>: The successful&nbsp;<sup>111</sup>In-labelling of biAb with retained binding to TfR and Aβ, and retained ability to enter the brain, demonstrated that&nbsp;<sup>111</sup>In can be used to generate radioligands for brain imaging. A high degree of [<sup>111</sup>In]biAb in bone marrow and intracellular accumulation in brain tissue indicated some off-target interactions or potential interaction with intrabrain TfR resulting in a relatively high non-specific background signal.</p> 2024-05-20T14:50:23-07:00 Copyright (c) 2024 Tobias Gustavsson, Matthias M. Herth, Dag Sehlin, Stina Syvänen https://ujms.net/index.php/ujms/article/view/10412 Trends in statin utilization and ischemic heart disease mortality in Lithuania and Sweden, 2000–2020 2024-05-16T11:46:45-07:00 Indre Treciokiene indre.treciokiene@mf.vu.lt Kamile Daukintyte kamile.daukintyte@gmail.com Paul Hjemdahl paul.hjemdahl@ki.se Björn Wettermark bjorn.wettermark@farmaci.uu.se <p><strong>Aims</strong>: To compare statin utilization and ischemic heart disease (IHD) mortality trends in Lithuania and Sweden and to assess correlations between the total utilization of statins and IHD mortality.</p> <p><strong>Methods</strong>: An ecological study assessing time trends in statin utilization (DDDs per 1000 inhabitants per day; DDD/TID) and IHD mortality in Lithuania and Sweden between 2000 and 2020. Statin utilization data in Lithuania were wholesale trade data, and Swedish data were drugs dispensed at pharmacies. IHD mortality data were extracted from national databases as rates per 100 000 inhabitants. Associations between statin utilization and IHD mortality in Lithuania and Sweden were examined using Spearman’s rank and Pearson’s correlation coefficients, respectively.</p> <p><strong>Results</strong>: Statin utilization increased from 16.8 to 135.8 DDD/TID in Sweden and from 0.2 to 61.8 DDD/TID in Lithuania between 2000 and 2020. Medium intensity was the most common statin dosage in Lithuania, while Sweden used more high intensity than moderate-intensity statins from 2017. IHD mortality in Lithuania remained high between 2000 and 2020 (from 359.1 to 508.8 deaths per 100 000 population), while it decreased markedly in Sweden (from 226.87 to 88.7 deaths per 100 000 population). IHD mortality and statin utilization were inversely correlated in Sweden (r = -0.993,&nbsp;<em>P</em>&nbsp;&lt; 0.001), while a positive correlation was found in Lithuania (rs = 0.871,&nbsp;<em>P</em>&nbsp;&lt; 0.001).</p> <p><strong>Conclusion</strong>: Despite the growing statin utilization in both countries, Lithuania recorded a slight increase in IHD mortality rates unlike the situation in Sweden. This indicates room for improvement in the management of modifiable cardiovascular risk factors in Lithuania including how statins are prescribed and used in clinical practice.</p> 2024-05-16T11:41:32-07:00 Copyright (c) 2024 Indre Treciokiene, Kamile Daukintyte, Paul Hjemdahl, Björn Wettermark https://ujms.net/index.php/ujms/article/view/10560 Recommended dosages of analgesic and sedative drugs in intensive care result in a low incidence of potentially toxic blood concentrations 2024-05-09T10:50:10-07:00 Ulrica Lennborn ulrica.lennborn@akademiska.se Anna Johansson anna.johansson@rmv.se Erik Lindgren eckan.lindgren@gmail.com Elisabet I. Nielsen elisabet.nielsen@farmaci.uu.se Håkan Sandler hakan.sandler@rmv.se Maria Bertilsson maria.bertilsson@linkmedical.eu Robert Kronstrand robert.kronstrand@rmv.se Johan Ahlner kajahlner@gmail.com Fredrik C. Kugelberg fredrik.kugelberg@rmv.se Sten Rubertsson sten.rubertsson@akademiska.se <p><strong>Background</strong>: Standard dosages of analgesic and sedative drugs are given to intensive care patients. The resulting range of blood concentrations and corresponding clinical responses need to be better examined. The purpose of this study was to describe daily dosages, measured blood concentrations, and clinical responses in critically ill patients. The purpose was also to contribute to establishing whole blood concentration reference values of the drugs investigated.</p> <p><strong>Methods</strong>: A descriptive study of prospectively collected data from 302 admissions to a general intensive care unit (ICU) at a university hospital. Ten drugs (clonidine, fentanyl, morphine, dexmedetomidine, ketamine, ketobemidone, midazolam, paracetamol, propofol, and thiopental) were investigated, and daily dosages recorded. Blood samples were collected twice daily, and drug concentrations were measured. Clinical responses were registered using Richmond agitation-sedation scale (RASS) and Numeric rating scale (NRS).</p> <p><strong>Results</strong>: Drug dosages were within recommended dose ranges. Blood concentrations for all 10 drugs showed a wide variation within the cohort, but only 3% were above therapeutic interval where clonidine (57 of 122) and midazolam (38 of 122) dominated. RASS and NRS were not correlated to drug concentrations.</p> <p><strong>Conclusion</strong>: Using recommended dose intervals for analgesic and sedative drugs in the ICU setting combined with regular monitoring of clinical responses such as RASS and NRS leads to 97% of concentrations being below the upper limit in the therapeutic interval. This study contributes to whole blood drug concentration reference values regarding these 10 drugs.</p> 2024-05-09T10:48:28-07:00 Copyright (c) 2024 Ulrica Lennborn, Anna Johansson, Erik Lindgren, Elisabet I. Nielsen, Håkan Sandler, Maria Bertilsson, Robert Kronstrand, Johan Ahlner, Fredrik C. Kugelberg, Sten Rubertsson https://ujms.net/index.php/ujms/article/view/10349 A Japanese translation of the Swedish Universities Scales of Personality 2024-03-21T09:07:59-07:00 Lykke Silfwerbrand lykke.silfwerbrand@uu.se Lisa Ekselius lisa.ekselius@neuro.uu.se Yasuharu Koike koike@pi.titech.ac.jp Malin Gingnell malin.gingnell@psyk.uu.se <p><strong>Background</strong>: The Swedish Universities Scales of Personality (SSP) is a personality measurement tool with a short test battery of high psychometric quality, previously not availiable in Japanese.</p> <p><strong>Methods</strong>: We translated the SSP into Japanese and administered it to 103 Japanese nationals. For 11 of the 13 SSP scales in the Japanese version of the SSP (SSP-J11), the Cronbach’s alpha ranged from 0.50 to 0.82 with good internal scale reliability.</p> <p><strong>Results</strong>: A principal factor analysis replicated the previous work by identifying the same three principal dimensions of Neuroticism, Aggression, and Extraversion factors.</p> <p><strong>Conclusion</strong>: The resulting three-factor SSP-J11 shows acceptable reliability and should provide informative insights about personality traits in research and clinical practice in a Japanese context.</p> 2024-03-21T00:00:00-07:00 Copyright (c) 2024 Lykke Silfwerbrand, Lisa Ekselius, Yasuharu Koike, Malin Gingnell https://ujms.net/index.php/ujms/article/view/9407 Expression of HIF-α and their association with clinicopathological parameters in clinical renal cell carcinoma 2024-03-21T06:29:51-07:00 Raviprakash T. Sitaram raviprakash@umu.se Börje Ljungberg borje.ljungberg@umu.se <p><strong>Objectives</strong>: This study aimed to assess the cellular localization and expression levels of hypoxia-inducible factor (HIF) -α proteins (specifically HIF-1α, HIF-2α, and HIF-3α) that play a role in the hypoxia pathway and to determine their correlation with clinicopathological parameters and patient survival in renal cell carcinoma (RCC).</p> <p><strong>Materials and methods</strong>: Tissue microarray (TMA) with cores from 150 clear cell RCCs and 31 non-ccRCC samples. HIF-1α, HIF-2α, and HIF-3α antibodies were used for immunohistochemistry (IHC) of TMA to evaluate the cellular localization and expression levels of HIF-α proteins, specifically in relation to the hypoxia pathway.</p> <p><strong>Results</strong>: The expression levels of the HIF-α proteins were higher in the nucleus than in the cytoplasm. Furthermore, the nuclear expression levels of all HIF-α proteins were significantly higher in clear cell RCC (ccRCC) than in non-ccRCC. Cytoplasmic HIF-3α expression was also higher in ccRCC than in non-ccRCC, whereas cytoplasmic HIF-1α and HIF-2α expression levels were similar between the different RCC types. In ccRCC, nuclear HIF-1α expression levels correlated with both nuclear HIF-2α and HIF-3α levels, whereas cytoplasmic HIF-3α expression levels were associated with HIF-1α only.</p> <p>In non-ccRCC, there was a positive correlation observed between nuclear HIF-1α and HIF-3α expression, but no correlation was found with HIF-2α. In patients with ccRCC, the nuclear expressions of HIF-1α and HIF-3α was significantly associated with cancer-specific survival (CSS) in univariate analysis. This association was no longer evident in multivariate analysis. Notably, there was no correlation observed between nuclear HIF-2α expression and CSS in these patients. In contrast, cytoplasmic expression levels showed no association with CSS.</p> <p><strong>Conclusion</strong>: The expression levels of the three primary HIF-α proteins were found to be higher in the nucleus than in the cytoplasm. Furthermore, the results indicated that HIF-3α and HIF-1α expression levels were significant univariate factors associated with CSS in patients with clear cell RCC. These results highlight the critical role that HIF-3α and HIF-1α play in the hypoxia pathway.</p> 2024-03-21T06:27:01-07:00 Copyright (c) 2024 Raviprakash T. Sitaram, Börje Ljungberg https://ujms.net/index.php/ujms/article/view/10504 Age and co-morbidities as independent risk factors of infections leading to hospital admission in the last year of life among the elderly: A retrospective registry-based study 2024-03-14T04:19:35-07:00 Linda Björkhem-Bergman linda.bjorkhem-bergman@ki.se Torbjörn Schultz torbjornschultz@gmail.com Peter Strang peter.strang@ki.se <p><strong>Background</strong>: The immune system declines with age, but the impact of chronological age may be affected by sex, co-morbidities, and sociodemographic factors.</p> <p><strong>Objective</strong>: The article aims to study infections associated with hospital admission in the elderly in their last year of life and the impact of age, sex, co-morbidities, and sociodemographic factors.</p> <p><strong>Method</strong>: A retrospective study based on registry data covering all care visits in Stockholm Region, Sweden, for 7 years was conducted. All deceased subjects with at least one hospital admission with infection as the main diagnosis in the last year of life were compared with subjects with no such admission. Subjects were categorized into three different age-groups 65–79, 80–89, and 90 years and above. Co-morbidity was measured by the Charlson Comorbidity Index (CCI) and sociodemographic factors were assessed using the ‘Mosaic-system’. Subjects living in nursing homes were analyzed separately. Uni- and multivariable logistic regressions were conducted.</p> <p><strong>Results</strong>: Of the 55,238 subjects in the study population, 14,192 (26%) had at least one hospital admission due to infection in the last year of life. The risk of having a severe infection increased with age, adjusted odds ratio (OR): 1.30 (1.25–1.36), and 1.60 (1.52–1.69) for the age-groups 80–89 and ≥ 90 compared to the age-group 65–79. The most important factor for infection was a high co-morbidity score; adjusted OR: 1.75 (1.68–1.82). Male sex and living in a less affluent area were weaker risk factors for infections.</p> <p><strong>Conclusion</strong>: Chronological age and co-morbidities are independent risk factors of infections associated with hospital admission in the last year in life while male sex and sociodemographic factors have less impact.</p> 2024-03-13T00:00:00-07:00 Copyright (c) 2024 Linda Björkhem-Bergman, Torbjörn Schultz, Peter Strang https://ujms.net/index.php/ujms/article/view/10386 The relationship between game genre, monetization strategy and symptoms of gaming disorder in a clinical sample of adolescents 2024-03-07T07:26:31-08:00 Frida André frida.andre@med.lu.se Per Bore Per.Bore@skane.se Theo Toresson theo.toresson@rb.se Mitchell Andersson Mitchell.andersson@med.lu.se Emma Claesdotter-Knutsson Emma.claesdotter-knutsson@med.lu.se <p><strong>Background</strong>: Gaming disorder (GD) has been introduced as a new diagnosis in the International Classification of Disease 11 (ICD-11). Currently, there’s limited understanding of how various video games may differentially contribute to the risk of developing GD. The main aim of this study was to examine the relationship between individuals’ game genre preferences, their preferred games’ monetization strategies, and GD Symptoms.</p> <p><strong>Methods</strong>: A total of 85 patients undergoing treatment for GD at a child and youth psychiatric clinic were included in the study. Their preferred games were classified into five novel genres based on gameplay similarities and objectives, and further categorized based on their monetization strategy.</p> <p><strong>Results</strong>: Symptom burden of GD, measured with Game Addiction Scale for Adolescents (GASA), was highest for those playing Free-to-Play (F2P) games and lowest for Pay-to-Play (P2P) players. Players of Competitive Games endorsed higher GD symptom burden, whereas players of Story-driven games reported lower GD symptom burden. Symptoms of GD were associated with attention-deficit hyperactivity disorder (ADHD) diagnosis in males.</p> <p><strong>Conclusions</strong>: This study reveals that game genre preference is influenced by sex, age, and certain psychiatric diagnoses. The categorizing of games into genres is increasingly complex and our research introduces a novel categorization in a developing research field. The result of this study suggests that the monetization model is important to consider while trying to understand the relationship between game characteristics and GD symptoms.</p> 2024-03-07T00:00:00-08:00 Copyright (c) 2024 Frida André, Per Bore, Theo Toresson, Mitchell Andersson, Emma Claesdotter-Knutsson https://ujms.net/index.php/ujms/article/view/9856 Partly unequal receipt of healthcare in last month of life in amyotrophic lateral sclerosis: a retrospective cohort study of the Stockholm region 2024-02-08T02:51:23-08:00 Peter Strang peter.strang@ki.se Torbjörn Schultz torbjornschultz@gmail.com Anneli Ozanne anneli.ozanne@gu.se <p><strong>Context</strong>: In amyotrophic lateral sclerosis (ALS), equal care is important, given that the disease often has complex symptoms at the end of life.</p> <p><strong>Objectives</strong>: The aim was to study the possible associations between demographic and clinical factors, including age, sex, and frailty, with acute healthcare utilization in the last month of life, measured by emergency room (ER) visits, admissions to acute hospitals and, acute hospitals as place of death, among patients with ALS. A second aim was to study whether receipt of specialized palliative care (SPC) affects above-mentioned healthcare utilization.</p> <p><strong>Methods</strong>: Observational, retrospective study based on Region Stockholm’s administrative data warehouse (VAL) in Sweden. Data were retrieved for 2015–2021 and analyzed with descriptive statistics and logistic regression models.</p> <p><strong>Results</strong>: All deceased patients (<em>n</em>&nbsp;= 448) ≥18 years with ALS were included. The mean age was 70.5 years, 46% were women and 58% had risk of frailty according to Hospital Frailty Risk Score (HFRS). Ninety-nine (22%) were nursing home residents and 49% received SPC. The receipt of SPC in patients with ALS was equal in relation to gender, socio-economic standing, frailty, and age &lt;75 years. Patients ≥75 years, those with dementia and/or residing in nursing homes (NH) were less likely to receive SPC (<em>P</em>&nbsp;= 0.01,&nbsp;<em>P</em>&nbsp;= 0.03 and&nbsp;<em>P</em>&nbsp;= 0.002, respectively). Receipt of SPC reduced ER visits (29% vs. 48%,&nbsp;<em>P</em>&nbsp;&lt; 0.001) and deaths at hospital (12% vs. 48%,&nbsp;<em>P</em>&nbsp;&lt;0.001). Patients who were frail, had a higher risk of ER visits and were more likely to die at an acute hospital setting (<em>P</em>&nbsp;&lt; 0.001 and&nbsp;<em>P</em>&nbsp;= 0.004). NH residents were less likely to have ER visits and to die in hospital (<em>P</em>&nbsp;= 0.002 and&nbsp;<em>P</em>&nbsp;= 0.005).</p> <p><strong>Conclusions</strong>: The results indicate partly unequal distribution of palliative care, however the actual, individual preferences cannot be deducted from registry studies. All patients with ALS should be offered SPC when needed.</p> <p><strong>Key message</strong>: This register study shows that receipt of SPC in patients with ALS is equal in relation to gender, socioeconomic standing, frailty, and age &lt;75 years, while those ≥75 years, with dementia, or residing in NH were somewhat less likely to receive SPC. Receipt of SPC reduces ER visits and acute hospital admissions.</p> 2024-02-08T00:00:00-08:00 Copyright (c) 2024 Peter Strang, Torbjörn Schultz, Anneli Ozanne https://ujms.net/index.php/ujms/article/view/9618 A retrospective nationwide analysis of evolocumab use in Sweden and its effect on low-density lipoprotein cholesterol levels 2024-02-08T02:51:54-08:00 Maria K. Svensson maria.k.svensson@medsci.uu.se Stefan James stefan.james@ucr.uu.se Annica Ravn-Fischer annica.ravn-fischer@vgregion.se Guillermo Villa villag@amgen.com Lovisa Schalin lschalin@amgen.com Thomas Cars thomas.cars@sence.com Stefan Gustafsson stefan.gustafsson@sence.com Emil Hagström emil.hagstrom@ucr.uu.se <p><strong>Background</strong>: Treatment with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors reduces low-density lipoprotein cholesterol (LDL-C) levels and decreases the incidence of major ischaemic events in clinical trials. However, less is known about the efficacy of PCSK9 inhibition in clinical practice. This study aimed to describe the change in LDL-C levels over time and LDL-C goal achievement in patients with/without atherosclerotic cardiovascular disease (ASCVD), who were prescribed evolocumab in clinical practice, and to describe adherence to and persistence with treatment.</p> <p><strong>Methods</strong>: Patients in Sweden with at least one evolocumab prescription filled between July 2015 and May 2020 were included. Medical history and lipid-lowering therapy (LLT) were sourced from national registries. LDL-C levels before and after treatment initiation were assessed using medical records. Persistence with and adherence to evolocumab and oral LLT were assessed up to 12 months after treatment initiation using the refill-gap method and proportion of days covered, respectively.</p> <p><strong>Results</strong>: Of the 2,360 patients with at least one prescription for evolocumab, 2,341 were included; 1,858 had ASCVD. Persistence with (76%) and adherence to (86%) evolocumab were high throughout the 12 months following initiation. Mean LDL-C levels decreased by 53% (95% confidence interval [CI]: 51–55%) in patients adherent to evolocumab (<em>n</em>&nbsp;= 567) and 59% (95% CI: 55–63%) in patients adherent to evolocumab and oral LLT (<em>n</em>&nbsp;= 186). Similar reductions in LDL-C were observed in patients with/without ASCVD. Reduced LDL-C levels remained stable during follow-up. Amongst patients adherent to evolocumab and those adherent to evolocumab and oral LLT, 23 and 55% achieved the LDL-C goal of &lt;1.4 mmol/L, respectively.</p> <p><strong>Conclusions</strong>: The evolocumab LDL-C-lowering effect observed in clinical trials was confirmed in clinical practice in Sweden, particularly in patients also treated with oral LLT. During follow-up, adherence to and persistence with evolocumab were high, with stable reduced levels of LDL-C during observation.</p> 2024-02-01T00:00:00-08:00 Copyright (c) 2024 Maria K. Svensson, Stefan James, Annica Ravn-Fischer , Guillermo Villa, Lovisa Schalin , Thomas Cars, Stefan Gustafsson, Emil Hagström https://ujms.net/index.php/ujms/article/view/10741 Cost-effectiveness analysis of transcatheter aortic valve implantation versus surgical aortic valve replacement in patients with severe aortic stenosis at low risk of surgical mortality in Sweden 2024-11-11T02:07:19-08:00 Konrad Nilsson konrad.nilsson@medsci.uu.se Stefan James stefan.james@ucr.uu.se Oskar Angerås oskar.angeras@vgregion.se Jenny Backes jenny.backes@regionorebrolan.se Henrik Bjursten henrik.bjursten@med.lu.se Pascal Candolfi Pascal_Candolfi@edwards.com Mattias Götberg matthias.gotberg@gmail.com Henrik Hagström Henrik.Hagstrom@regionvasterbotten.se Chiara Malmberg chiara.malmberg@ihe.se Niels Erik Nielsen Niels.Erik.Nielsen@regionostergotland.se Archita Sarmah Archita_Sarmah@edwards.com Magnus Settergren magnus.settergren@regionstockholm.se Tom Bromilow tom.bromilow@york.ac.uk <p><strong>Background</strong>: Transcatheter aortic valve implantation (TAVI) has shown similar or improved clinical outcomes compared with surgical aortic valve replacement (SAVR) in patients with symptomatic severe aortic stenosis at low risk for surgical mortality. This cost-utility analysis compared TAVI with SAPIEN 3 versus SAVR in symptomatic severe aortic stenosis patients at low risk of surgical mortality from the perspective of the Swedish healthcare system.</p> <p><strong>Methods</strong>: A published, two-stage, Markov-based cost-utility model that captured clinical outcomes from the&nbsp;<em>Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated according to Recommended Therapies</em>&nbsp;(SWEDEHEART) registry (2018–2020) was adapted from the perspective of the Swedish healthcare system using local general population mortality, utility and costs data. The model had a lifetime horizon. Model outputs included changes in direct healthcare costs and health-related quality of life from using TAVI as compared with SAVR.</p> <p><strong>Results</strong>: TAVI with SAPIEN 3 resulted in lifetime costs per patient of 940,541 Swedish krona (SEK) and lifetime quality-adjusted life years (QALYs) per patient of 7.16, whilst SAVR resulted in lifetime costs and QALYs per patient of 821,380 SEK and 6.81 QALYs, respectively. Compared with SAVR, TAVI offered an incremental improvement of +0.35 QALY per patient at an increased cost of +119,161 SEK per patient over a lifetime horizon, resulting in an incremental cost-effectiveness ratio of 343,918 SEK per QALY gained.</p> <p><strong>Conclusion</strong>: TAVI with SAPIEN 3 is a cost-effective option versus SAVR for patients with symptomatic severe aortic stenosis at low risk for surgical mortality treated in the Swedish healthcare setting. These findings may inform policy decisions in Sweden for the management of this patient group.</p> 2024-11-11T00:00:00-08:00 Copyright (c) 2024 Konrad Nilsson, Stefan James, Oskar Angerås, Jenny Backes, Henrik Bjursten, Pascal Candolfi, Mattias Götberg, Henrik Hagström, Chiara Malmberg, Niels Erik Nielsen, Archita Sarmah, Magnus Settergren, Tom Bromilow https://ujms.net/index.php/ujms/article/view/9863 COVID-19: Not a thrombotic disease but a thromboinflammatory disease 2024-01-24T06:10:34-08:00 Shu He heshu9999@gmail.com Margareta Blombäck emma.csemiczky@openacademia.net Håkan Wallén emma.csemiczky@openacademia.net <p>While Coronavirus Disease in 2019 (COVID-19) may no longer be classified as a global public health emergency, it still poses a significant risk at least due to its association with thrombotic events. This study aims to reaffirm our previous hypothesis that COVID-19 is fundamentally a thrombotic disease. To accomplish this, we have undertaken an extensive literature review focused on assessing the comprehensive impact of COVID-19 on the entire hemostatic system. Our analysis revealed that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection significantly enhances the initiation of thrombin generation. However, it is noteworthy that the thrombin generation may be modulated by specific anticoagulants present in patients’ plasma. Consequently, higher levels of fibrinogen appear to play a more pivotal role in promoting coagulation in COVID-19, as opposed to thrombin generation. Furthermore, the viral infection can stimulate platelet activation either through widespread dissemination from the lungs to other organs or localized effects on platelets themselves. An imbalance between Von Willebrand Factor (VWF) and ADAMTS-13 also contributes to an exaggerated platelet response in this disease, in addition to elevated D-dimer levels, coupled with a significant increase in fibrin viscoelasticity. This paradoxical phenotype has been identified as ‘fibrinolysis shutdown’. To clarify the pathogenesis underlying these hemostatic disorders in COVID-19, we also examined published data, tracing the reaction process of relevant proteins and cells, from ACE2-dependent viral invasion, through induced tissue inflammation, endothelial injury, and innate immune responses, to occurrence of thrombotic events. We therefrom understand that COVID-19 should no longer be viewed as a thrombotic disease solely based on abnormalities in fibrin clot formation and proteolysis. Instead, it should be regarded as a thromboinflammatory disorder, incorporating both classical elements of cellular inflammation and their intricate interactions with the specific coagulopathy.</p> 2024-01-22T00:00:00-08:00 Copyright (c) 2024 Shu He, Margareta Blombäck, Håkan Wallén